Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

MolDX lists two assays for monitoring response to immune-checkpoint inhibitor therapy

The MolDX billing article A58434, in the revision effective January 1, 2026, lists Signatera for monitoring response to immune-checkpoint inhibitor therapy in advanced solid tumors and Guardant Response for inoperable or metastatic solid tumors.

CMS MolDX